Nexium Capsules LDA Specific Clinical Experience Investigation

Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With LDA

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01729182

Enrollment

2363

Registered

2012-11-20

Start date

2013-01-01

Completion date

2017-03-09

Last updated

2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duodenal Ulcer, Gastric Ulcer

Keywords

Low dose Aspirin(LDA), Gastric ulcer or duodenal ulcer, Nexium

Brief summary

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Detailed description

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Exclusion criteria

* Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy). * Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Design outcomes

Primary

Measure	Time frame	Description
Adverse events incidence	Up to 2 years	Number of Adverse Drug Reactions

Secondary

Measure	Time frame
Non-recurrence rate of peptic ulcer	Up to 2 years

Countries

Japan

Outcome results